Free accessAnnouncementFirst published online 2004-2
Relative Prognostic Value of Self-Reported Adherence and Plasma Nnrti/Pi Concentrations to Predict Virological Rebound in Patients Initially Responding to Haart
We studied the predictive value of self-reported adherence and plasma drug concentrations on virological rebound to HAART. Among 238 participants in the AdICoNA study who had viral load ≤500 copies/ml, 42 (17.6%) experienced virological rebound by 96 weeks. Both self-reported non-adherence and sub-optimal concentration were independently associated with a higher risk of virological rebound.
References
1.
Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents.July 2003 Practices for treatment of HIV developed by the panel on clinical practices for treatment of HIV infection convened by the Department of Health and Human Services (DHHS) and the Henry J Kaiser Family Foundation.
2.
MocroftA., GillM.J., DavidsonW., & PhillipsA.N.Predictors of a viral response and subsequent virological treatment failure in patients with HIV starting a protease inhibitor.AIDS1998; 12: 2161–2167.
3.
LedergerberB., EggerM., OpravilM., TelentiA., HirshcelB., BattegayM., VernazzaP., SudreP., FleppM., FurrerH., FrancioliP., & WeberR. for the Swiss HIV Cohort Study. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study.Lancet1999; 353: 863–868.
4.
StaszewskiS., MillerV., SabinC., CarlebachA., BergerA.M., WeidmannE., HelmE.B., HillA., & PhillipsA.N.Virological response to protease inhibitor in an HIV clinic cohort.AIDS1999; 13: 367–373.
5.
MillerV., StaszewskiS., SabinC., CarlebachA., RottmanC., WeidmannE., RabenauH., HillA., Cozzi-LepriA., & PhillipsA.N.CD4 lymphocyte count as predictor of the duration of highly active antiretroviral therapy-induced suppression of human immunodeficiency virus load.Journal of Infectious Diseases1999; 180: 530–533.
6.
ParedesR., MocroftA., KirkO., LazzarinA., BartonS.E., Van LunzenJ., KatzensteinT.L., AntunesF., LundgrenJ.D., & ClotetB. for the EuroSIDA Study Group. Predictors of virological success and ensuing failure in HIV-positive starting highly active antiretroviral therapy in Europe. Results from the EuroSIDA Study.Archives of Internal Medicine2000; 160: 1123–1132.
7.
BangsbergD.R., HechtF.M., CharleboisE.D., ZolopaA.R., HolodniyM., SheinerL., BambergJ.D., ChesneyM.A., & MossA.Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population.AIDS2000; 14: 357–366.
8.
HaubrichR.H., LittleS.J., CurrierJ.S., ForthalD.N., KemperC.A., BeallG.N., JohnsonD., DubèM.P., HwangJ.Y., & McCutchanJ.A. and the California Collaborative Treatment Group. The value of patient-reported adherence to anti-retroviral therapy in predicting virologic and immunologic response.AIDS1999; 13: 1099–1107.
9.
PatersonD.L., SwindellsS., MohrJ., BresterM., VergisE.N., SquierC., WagenerM.M., & SinghN.Adherence to protease inhibitor therapy and outcomes in patients with HIV infection.Annals of Internal Medicine2000; 133: 21–30.
10.
HoetelmansR.M., ReijersM.H., WeverlingG.J., Ten KateR.W., WitF.W.N.M., MulderJ.W., WeigelH.M., FrissenJ.P.H., RoosM., JurriaansS., SchitemakerH., de WolfF., BeijnenJ.H., & LangeJ.M.A.The effect of plasma drug concentrations on HIV-1 clearance rate during quadruple drug therapy.AIDS1998; 12: F111–F115.
11.
DurantJ., ClevenberghP., GarraffoR., HalfonP., IcardS., Del GiudiceP., MontagneN., SchapiroJ.M., & DellamonicaP.Importance of protease inhibitor plasma levels in HIV-infected patients treated with genotypic-guided therapy: pharmacological data from the Viradapt Study.AIDS2000; 14: 1333–1339.
12.
AmmassariA., MurriR., PezzottiP., TrottaM.P., RavasioL., De LongisP., Lo CaputoS., NarcisoP., PauluzziS., CarosiG., NappaS., PianoP., IzzoC.M., LichtnerM., RezzaG., IppolitoG., d'Arminio MonforteA., WuA.W., & AntinoriA. for the AdICONA Study Group. Self-reported symptoms and medication side effects influence adherence to HAART in persons with HIV infection.Journal of Acquired Immune Deficiency Syndromes2001; 28: 445–449.
13.
D'Arminio MonforteA., Cozzi-LepriA., RezzaG., PezzettiP., AntinoriA., PhillipsA.N., AngaranoG., Col AngeliV., De LucaA., IppolitoG., MaggeseL., SosciaF., FiliceG., GrittiF., NarcisoP., TirelliU., & MoroniM. for The I.CO.N.A. Study Group. Insights into reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naïve patients.AIDS2000; 14: 499–507.
14.
MurriR.Ammassari A, Gallicano K, De Luca A, Cingolani A, Jacobson D, Wu AW & Antinori A. Patient-reported nonadherence to HAART is related to protease inhibitor levels.Journal of Acquired Immune Deficiency Syndromes2000; 24: 123–128.
15.
Low-Beer, YipB., O'ShaughnessyM.V., HoggR.S., & MontanerJ.S.G.Adherence to triple therapy and viral load response.Journal of Acquired Immune Deficiency Syndromes2000; 23: 360–361.
16.
GiffordA.L., BormannJ.E., ShivelyM.J., WrightB.C., RichmanD.D., & BozzetteS.A.Predictors of self-reported adherence and plasma HIV concentrations in patients on multidrug antiretroviral regimens.Journal of Acquired Immune Deficiency Syndromes2000; 23: 386–395.
17.
Le MoingV., CheneG., CarrieriM.P., AlioumA., Brun-VezinetF., PirothL., CassatoJ.P., MoattiJ.P., RaffiF., LeportC., & the APROCO Study Group. Predictors of virological rebound in HIV-1 infected patients initiating a protease inhibitor-containing regimen.AIDS2002; 16: 21–29.
18.
BurgerD.M., HoetelmansR.M., HugenP.W., MulderJ.W., MeenhorstP.L., KoopmansP.P., BrinkmanK., KeuterM., DolmansW., & HeksterY.A.Low plasma concentrations of indinavir are related to virological treatment failure in HIV-1-infected patients on indinavir-containing triple therapy.Antiviral Therapy1998; 3: 215–220.
19.
ReijersM.H., WeigelH.M., HartA.A., Ten KateR.W., MulderJ.W., ReissP., SchuitemakerH., HoetelmansR.M., WeverlingG.J., & LangeJ.M.Toxicity and drug exposure in a quadruple drug regimen in HIV-1 infected patients participating in the ADAM Study.AIDS2000; 14: 59–67.
20.
VeldkampA.I., WeverlingG.J., LangeJ.M., MontanerJ.S., ReissP., CooperD.A., VellaS., HallD., BeijnenJ.H., & HoetelmansR.M.High exposure to nevirapine in plasma is associated with an improved virological response in HIV-1 infected individuals.AIDS2001; 15: 1089–1095.
21.
MarzoliniC., TelentiA., DecosterdL.A., GreubG., BiollazJ., & BuslinT.Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients.AIDS2001; 15: 71–75.
22.
FletcherC.V., AndersonP.L., KakudaT.N., SchackerT. W., HenryK., GrossC.R., & BrundageR.C.Concentration-controlled compared with conventional antiretroviral therapy for HIV infection.AIDS2002; 16: 551–560.
23.
BurgerD., HugenP., ReissP., GyssensI., SchneiderM., KroonF., SchreijG., BrinkmanK., RichterC., PrinsJ., AarnoutseR., & LangeJ. for the ATHENA Cohort Study Group. Therapeutic drug monitoring of nelfinavir and indinavir in treatment-naive HIV-1-infected individuals.AIDS2003; 17: 1157–1165.
24.
DescampsD., FlandreP., CalvezV., PeytavinG., MeiffredyV., CollinG., DelaugerreC., Robert-DelmasS., BazinB., AboulkerJ. P., PialouxG., RaffiF., & Brun-VezinetF. for the Trilege Study Team. Mechanisms of virologic failure in previously untreated HIV-infected patients from a trial of induction-maintenance therapy.Journal of the American Medical Association2000; 283: 205–211.
25.
AlexanderC.S., AsselinJ.J., TingL.S.L., MontanerJ.S.G., HoggR.S., YipB., O'ShaughnessyM.V., & HarriganP.R.Antiretroviral concentrations in untimed plasma samples predict therapy outcome in a population with advanced disease.Journal of Infectious Diseases2003; 188: 541–548.
26.
LiuH., GolinC.E., MillerL.G., HaysR.D., BeckC.K., SanandajiS., ChristianJ., MadonatoT., DuranD., KaplanA.H., & WegnerN.S.A Comparison study of multiple measures of adherence to HIV protease inhibitor.Annals of Internal Medicine2001; 134: 968–977.
27.
NieuwkerkP.T., SprangersM.A., BurgerD.M., HoetelmansR.M., HugenP.W., DannerS.A., Van Der EndeM.E., SchneiderM.M., SchreyG., MeenhorstP.L., SpregerH.G., KauffmannR.H., JambroesM., ChesneyM.A., De WolfF., & LangeJ.M. for the ATHENA Project. Limited patient adherence to highly active antiretroviral therapy for HIV-1 infection in an observational cohort study.Archives of Internal Medicine2001; 161: 1962–1968.
